Table 1.
Demographic and clinical characteristics of study population.
| Variables | Qiaokou cohort (training set) | P* | Caidian cohort (validation set) | P* | P † | ||
|---|---|---|---|---|---|---|---|
| ATB (n = 40) | LTBI (n = 50) | ATB (n = 29) | LTBI (n = 35) | ||||
| Age, years | 50.8 ± 18.2 | 48.9 ± 16.7 | 0.529 | 52.0 ± 17.0 | 53.1 ± 15.7 | 0.981 | 0.351 |
| Sex, male, % | 25 (62.5%) | 31 (62.0%) | 0.961 | 17 (58.6%) | 21 (60.0%) | 0.911 | 0.721 |
| Underlying condition or illness | |||||||
| HIV infection | 1 (2.5%) | 0 (0.0%) | 0.261 | 1 (3.5%) | 0 (0.0%) | 0.268 | 0.807 |
| Diabetes mellitus | 7 (17.5%) | 7 (14.0%) | 0.649 | 5 (17.2%) | 3 (8.6%) | 0.296 | 0.593 |
| Solid tumor | 5 (12.5%) | 4 (8.0%) | 0.48 | 3 (10.3%) | 4 (11.4%) | 0.89 | 0.851 |
| Hematological malignancy | 3 (7.5%) | 1 (2.0%) | 0.208 | 2 (6.9%) | 1 (2.9%) | 0.447 | 0.943 |
| Liver cirrhosis | 2 (5.0%) | 1 (2.0%) | 0.431 | 2 (6.9%) | 3 (8.6%) | 0.804 | 0.217 |
| End-stage renal disease | 5 (12.5%) | 3 (6.0%) | 0.282 | 5 (17.2%) | 3 (8.6%) | 0.296 | 0.469 |
| Organ transplantation | 2 (5.0%) | 0 (0.0%) | 0.11 | 1 (3.5%) | 1 (2.9%) | 0.892 | 0.729 |
| Immunosuppressive condition‡ | 7 (17.5%) | 7 (14.0%) | 0.649 | 4 (13.8%) | 3 (8.6%) | 0.505 | 0.411 |
| Positive culture for MTB | 30 (75.0%) | N/A | N/A | 25 (86.2%) | N/A | N/A | N/A |
| Positive GeneXpert MTB/RIF | 31 (77.5%) | N/A | N/A | 22 (75.9%) | N/A | N/A | N/A |
ATB, active tuberculosis; LTBI, latent tuberculosis infection; MTB, Mycobacterium tuberculosis; N/A, not applicable. *Comparisons were performed between ATB and LTBI groups using Mann-Whitney U test, Chi-square test, or Fisher’s exact test. †Comparisons were performed between Qiaokou and Caidian cohorts using Mann-Whitney U test, Chi-square test, or Fisher’s exact test. ‡Patients who underwent chemotherapy or took immunosuppressants within 3 months. Data were presented as means ± SD or numbers (percentages).